Journal article icon

Journal article

Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high grade serous ovarian and squamous non-small cell lung cancer

Abstract:

We have previously shown that raised p-S6K levels correlate with resistance to chemotherapy in ovarian cancer. We hypothesised that inhibiting p-S6K signalling with the dual m-TORC1/2 inhibitor in patients receiving weekly paclitaxel could improve outcomes in such patients.In dose escalation, weekly paclitaxel (80 mg/m2) was given 6/7 weeks in combination with two intermittent schedules of vistusertib (dosing starting on the day of paclitaxel): schedule A, vistusertib dosed bd for 3 consecuti...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1093/annonc/mdy245

Authors


Expand authors...
More from this funder
Grant:
*Grant Number Example*
More from this funder
Funding agency for:
Banerji, U
Grant:
RP-2016-07-028
Publisher:
Oxford University Press Publisher's website
Journal:
Annals of Oncology Journal website
Volume:
29
Issue:
9
Pages:
1918–1925
Publication date:
2018-07-17
Acceptance date:
2018-06-29
DOI:
EISSN:
1569-8041
ISSN:
0923-7534
Pmid:
30016392
Source identifiers:
890093
Language:
English
Keywords:
Pubs id:
pubs:890093
UUID:
uuid:4dd86687-f429-4b43-9b11-c9c06de0a5c7
Local pid:
pubs:890093
Deposit date:
2018-08-14

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP